PHA RESEARCH PROGRAMS
The Pulmonary Hypertension Association’s (PHA’s) strategic plan directs activities toward achieving our mission to extend and improve the lives of those affected by pulmonary hypertension (PH) and reaching our vision of a world without PH, empowered by hope.
Catalyzing research for a cure is incorporated in PHA’s strategic plan to:
- Provide grants for innovative adult and pediatric research projects across a broad range of PH topics and institutions nationwide.
- Support the next generation of physician-researchers and scientists focusing on adult and pediatric PH through fellowships, young investigators’ awards, and early career grants for difficult-to-fund research projects.
- Collaborate with PH and associated disease patients, health and science professionals, government, and other organizations, to advise and gather new knowledge and information to share with the PH community effectively, rapidly, and broadly.
Innovation in PH Research Award
PHA’s latest grant supports new areas of pulmonary hypertension research that couldn’t have been explored without PHA funding. Up to $60,000 a year for two years is available. Any areas of innovative pulmonary hypertension research will be accepted.
U.S. citizens, permanent residents, or non-residents working at U.S.-based institutions. Applicants must have Ph.D. degrees or equivalent; doctoral-level clinical degrees in public health or other health science (such as M.D., D.O., PharmD or Ph.D.); and have completed all fellowship or post-doctoral training.
Applications are due at 5 p.m. EDT Aug. 1. Apply here.
Policy and Guidelines for our Innovation Research Award (pdf)
Aldrighetti Research Award for Young Investigators
Named for PHA’s first president and CEO, Rino Aldrighetti, this award was established in 2016 at PHA’s 12th International PH Conference and Scientific Sessions with sponsorship from Janssen Pharmaceuticals, Inc, a division of Johnson & Johnson. The program supports the careers of young investigators who likely will make a strong, sustained impact in PH research. Proposals should be directed towards understanding biological pathways and identifying novel therapeutic targets or biomarkers of pulmonary arterial hypertension (PAH). Learn more about the Aldrighetti Research Award.
The application deadline for this grant cycle is March 15, 2022. Awards may be approved for funding up to a two (2) year period for up to $40,000/year. Refer to the Policy and Guidelines for the Aldrighetti Research Award.
Log-in at proposalCENTRAL to apply.
Contact gro.noitaicossAHP@hcraeseR with any questions.
Learn more about recent Aldrighetti awardees.
PHA Research in Action
Since forming in 1991, PHA has committed $8 million to support cutting-edge research on PH and supported more than 75 researchers.
PHA grants support promising PH scientists and clinicians who study new methods for early detection, new treatments to prevent the onset of PH, and ultimately a cure. PHA also advances research through the PHA Registry and PVDOMICS initiatives. PH health care professionals share information about their research with their colleagues through posters and presentations at PHA’s PHPN Symposium.
PHA Grant Awardees
PHA has funded PH clinicians and scientists supporting PH pediatric and adult research through the Aldrighetti Research Award, the Robyn J. Barst pediatric PH Research and Mentoring Grant, PHA/ATS Research Fellowships, PHA Proof of Concept Awards and PHA/NHLBI Mentoring Clinical Scientist Awards. Learn more about previous PHA grant awardees.
The PHA Registry (PHAR) is the largest active U.S.-based, prospective and longitudinal observational PH patient registry. More than 55 participating PHA-accredited PH Care Centers have enrolled over 1,350 individuals in PHAR. Patients with PAH, CTEPH and pediatric PH due to developmental lung disease may be enrolled in PHAR. Goals of the PHAR are to support research towards measuring and improving quality of care, understand risk factors for patient outcomes, and supporting clinical research for new therapies. There are more than 25 research proposals, multiple conference abstracts, and 4 publications using data from PHAR.
The PVDOMICS study (Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics) is a partnership between PHA and the National Heart, Lung and Blood Institute at the National Institutes of Health. PVDOMICS uses clinical and biological “omics” data from all PH (Groups 1 through 5) classifications. The study aims to identify new ways to group PH patients and new biological measurements that ultimately could lead to breakthroughs in diagnosis, outcomes and therapies. The PVDOMICS investigators have presented study progress at various research and medical conferences and multiple writing committees are underway for publications. See the PVDOMICS page for details.
PHA Conference Research Room
Each biennial meeting of the PHA International PH Conference and Scientific Sessions provides an opportunity for PH patients to participate in research studies and PH clinician-researchers to enroll patients in studies. The PHA Research Room enables researchers to collect patient data, including biological specimens (i.e. cheek swabs and blood samples). At the 2018 Conference in Orlando, Florida, 10 research teams from all over the U.S. and more than 200 Conference attendees participated in studies in the PHA Research Room. Learn more about the PHA Conference Research Room.
Presentations and posters are presented at the biennial PHA Pulmonary Hypertension Professional Network (PHPN) Symposium. Attendees hear about cutting-edge research and case studies, attend lightning round presentations of selected abstracts and talk to abstract authors during the accredited Poster Hall session featuring research on the basics of PH diagnosis, treatment and management.
Advances in Pulmonary Hypertension, the official journal of the Pulmonary Hypertension Association, is the world’s first medical journal dedicated to pulmonary hypertension. The journal is directed by an editorial board of renowned PH experts with the oversight of PHA’s Scientific Leadership Council. Published quarterly online, Advances has readers from 129 countries around the world.
Dr. Todd Bull, professor of medicine, pulmonary sciences and critical care at University of Colorado, discusses biological pathways targeted for drug development and models and technology that support PH research.